Pfizer 4Q Adj. EPS Misses Est.
Source: BFW (Bloomberg First Word)
Tickers
PFE US (Pfizer Inc)
People
Frank D'Amelio (Pfizer Inc)
Ian Read (Pfizer Inc)
To de-activate this alert, click here
UUID: 7947283
(Bloomberg) -- Pfizer 4Q adj. EPS 47c, est. 50c (range 47c-57c)
Alert: HALISTER- 4Q adj. rev. $13.6b, est. $13.6b (range $12.9b-$14.4b)
- 4Q Lyrica rev. $1.24b, est. $1.22b (Bloomberg data)
- 4Q Viagra rev. $284m, est. $399.8m
- 4Q Prevnar franchise rev. $1.42b, est. $1.67b (average of 9)
- 4Q Ibrance rev. $643m, est. $592.9m (average of 9)
- 4Q Xalkori rev. $145m, est. $143.2m (average of 5)
- 4Q Enbrel rev. $708m, est. $700.3m
- 4Q Xeljanz rev. $278m, est. $240.8m
- 4Q Lipitor rev. $464m, est. $423.8m
- Sees FY17 rev. $52.0b to $54.0b
- Sees FY17 adj. EPS $2.50 to $2.60
- Sees Share Repurchases of $5.0b in 2017
- View Reflects Pending Disposition of Hospira Infusion
- 13 buys, 13 holds, 0 sells before today
- Call 10am (NY time), (866)-662-3198 pw FourthQuar
Source: BFW (Bloomberg First Word)
Tickers
PFE US (Pfizer Inc)
People
Frank D'Amelio (Pfizer Inc)
Ian Read (Pfizer Inc)
To de-activate this alert, click here
UUID: 7947283